Xalkori Articles
IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib
14 May 2013
Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF
27 March 2013
US and European oncologists see novel chemotherapies as best hope for soft tissue sarcoma
30 January 2013
Conditional European approval for Pfizer's Xalkori
25 October 2012
ESMO 2012 Congress highlights
1 October 2012
Pfizer and Roche hope to score with ESMO presentations, notes GlobalData
25 September 2012
75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch
21 June 2012
Showing 1-10 of 10 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
